TC
CNCE

TFS Capital’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

TFS Capital’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-23,683
Closed -$330K – 423
2017
Q2 		$330K Buy
+23,683
New +$349K 0.13% 311
2017
Q1 		– Sell
-22,749
Closed -$234K – 906
2016
Q4 		$234K Buy
22,749
+3,649
+19% +$33.4K 0.06% 466
2016
Q3 		$193K Buy
19,100
+656
+4% +$7.17K 0.05% 566
2016
Q2 		$207K Sell
18,444
-114,740
-86% -$1.46M 0.04% 719
2016
Q1 		$1.82M Buy
133,184
+29,050
+28% +$418K 0.26% 90
2015
Q4 		$1.98M Sell
104,134
-278,062
-73% -$6.04M 0.21% 167
2015
Q3 		$7.17M Buy
382,196
+330,669
+642% +$5.62M 0.69% 2
2015
Q2 		$767K Buy
51,527
+16,129
+46% +$246K 0.07% 406
2015
Q1 		$536K Sell
35,398
-89,104
-72% -$1.24M 0.05% 525
2014
Q4 		$1.66M Buy
124,502
+100,404
+417% +$1.3M 0.16% 184
2014
Q3 		$304K Buy
24,098
+7,921
+49% +$76.8K 0.03% 742
2014
Q2 		$163K Buy
+16,177
New +$156K 0.01% 988

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

TFS Capital's CNCE Position: Q3 2017 in Review

TFS Capital sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2017, closing a stake of 23,683 shares — an estimated $330K sold.

TFS Capital first reported a position in CNCE in Q2 2014 and held it in 12 quarters. The position peaked at $7.17M in Q3 2015. 79 funds tracked by Wall St. Rank hold CNCE as of Q3 2017.

  • TFS Capital reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 23,683 Concert Pharmaceuticals, Inc. shares in Q3 2017, an estimated $330K.
  • TFS Capital first reported a position in Concert Pharmaceuticals, Inc. in Q2 2014 and held it in 12 quarters.
  • TFS Capital's Concert Pharmaceuticals, Inc. position peaked at $7.17M in Q3 2015.
  • 79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.